Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Ochsner Health System
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03309592CT.gov Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension | — | Withdrawn | — | — | — |
NCT00879229CT.gov ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pulmonary Hypertension
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ambrisentan (this asset) | Ochsner Health System | Approved | CCC · 53 |
| Sildenafil | Duke University | P4 | BB |
| Epoprostenol | National Center for Research Resources (NCRR) | P4 | BB |
| Tadalafil | Ochsner Health System | P4 | B |
| ut-15 | United Therapeutics | P3 | B |
| Uniprost | University of California, San Diego | P3 | B |
| Bosentan | Royal Brompton & Harefield NHS Foundation Trust | P4 | B |
| Bardoxolone Methyl Ester | Biogen | P2 | B |
| Iloprost | Actelion | P2 | B |
+20 more in the Pulmonary Hypertension cohort
Other indications for Ambrisentan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | P4 | CCC · 52 |
| Idiopathic Pulmonary Fibrosis | — | P3 | CC · 45 |
| Portal Hypertension | — | P2 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ambrisentan in Pulmonary Hypertension. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ambrisentan-pulmonary-hypertension-27179
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →